PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors

The results show that by adjusting the formulation conditions, it is possible to obtain PLGA:poloxamer micro- and nanoparticles with very high drug loadings, and with the capacity to release the active compound in a controlled way for up to one month

Yolanda Parajó


Scholarcy highlights

  • Tissue engineering is one of the most promising research areas in bioregenerative medicine
  • The use of proangiogenic molecules delivered from a controlled release device is a promising strategy to induce tissue vascularization
  • The controlled release system can enhance the therapeutic effect in vivo of many short half-life drugs, while circumventing the need for repeated administrations
  • PLGA:poloxamer blend based micro- and nanoparticles have been developed for the sustained delivery of a recently developed synthetic proangiogenic compound: SHA-2-22
  • Drug-loaded PLGA:poloxamer blend microparticles were prepared by an oil-in-oil solvent extraction/evaporation technique
  • In vitro cell assays performed in an endothelial cell model confirmed the bioactivity of SHA-22-2 encapsulated in PLGA:poloxamer microparticles

Need more features? Save interactive summary cards to your Scholarcy Library.